Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 65Kidney Neoplasms 18Neoplasms 16Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 10Colorectal Neoplasms 8Carcinoma, Hepatocellular 8Carcinoma 8Melanoma 7Glioblastoma 5Clear-cell metastatic renal cell carcinoma 5Lung Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Ovarian Neoplasms 3Endometrial Neoplasms 3Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Skin Neoplasms 2Sarcoma 2Pheochromocytoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Paraganglioma 2Liver Neoplasms 2Kidney Diseases 2Carcinoma, Adenoid Cystic 2Breast Neoplasms 2Advanced Solid Tumors 2

Interventions

tremelimumab 1ixabepilone 1durvalumab 1ST 1481 1Paclitaxel 1Fulvestrant 1Docetaxel 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Malignancies × Axitinib × Clear all
NCT01540526 2019-11-19

Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib

University of Wisconsin, Madison

Phase 1 Completed
24 enrolled
Genitourinary

Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡